Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Scientific Publications

Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV 1 envelope trimers in non human primates

Read more

Scientific Publications

Description of adverse events among adult men following voluntary medical male circumcision Findings from a circumcision programme in two provinces of South Africa

Read more

Features

IAVI launches Leadership Development Program to strengthen scientific research in Africa and India

August 9, 2021

New leadership program positions homegrown scientists to drive research into HIV and other infectious diseases in Africa and India.

Read more

Features

Europe-Africa research partnership launches HIV vaccine clinical trial in three African countries

August 3, 2021

Vaccine candidate targets vulnerabilities common across many HIV-1 variants.

Read more

Scientific Publications

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV 1 Broadly Neutralizing Antibodies PGT121 PGDM1400 and VRC07 523 LS

Read more

Videos

Broadly neutralizing antibodies and their use in HIV research

July 29, 2021

Antibodies are natural proteins that the body makes that fight disease. Broadly neutralizing antibodies (bnAbs) are a special kind of antibody that is now being researched to see how they can play a role in HIV prevention. IAVI translates scientific discoveries into affordable, globally accessible public health solutions, and we believe all people should have access to innovative medicines.

Read more

In The News

100 years of a tuberculosis vaccine with limited benefit

Devex

July 15, 2021

Read more

Press Releases

Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials

July 14, 2021

Biofabri and IAVI announce their intention to partner on efficacy trials of the tuberculosis vaccine candidate MTBVAC TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19. COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.…

Read more